Yahoo Finance 
Global Cancer Gene Therapy Market Report 2022: Surge in Government Support & Biotechnological Funding Driving Growth
Dublin, Sept. 08, 2022 (GLOBE NEWSWIRE) -- The "Cancer Gene Therapy Market By Therapy, By End User: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
Cancer Gene Therapy Market was valued at $1,389.42million in 2020 and is estimated to reach $11,359.35 million by 2030, registering a CAGR of 23.3% from 2021 to 2030.
Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer. Owing to the high success rate during the preclinical and clinical trials, cancer gene therapy has gained popularity.
Many techniques are used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of the gene whose function is abnormal. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells.
The rise in the prevalence of cancer, the benefits of cancer gene therapy over conventional cancer therapies, and the advancement in this field are the major factors that drive the market growth.
In addition, the surge in government support, ethical acceptance of gene therapy for cancer treatment, and rise in biotechnological funding encouraging the R&D activities for cancer gene therapy and thus fuel the growth of the cancer gene therapy market.
In addition rise in awareness regarding cancer gene therapy is a major factor that drives the global cancer gene therapy market growth.
In addition, an increase in government support for research in gene therapy, ethical acceptance of gene therapy for cancer treatment, and a rise in the prevalence of cancer boost the growth of the cancer gene therapy market. However, the high cost associated with the treatment and unwanted immune responses is expected to restrain the market growth.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer gene therapy market analysis from 2020 to 2030 to identify the prevailing cancer gene therapy market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the cancer gene therapy market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global cancer gene therapy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Therapy
Gene Induced Immunotherapy
Oncolytic Virotherapy
Gene Transfer
By End User
Hospitals
Diagnostic centers
Research Institutes
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Bristol Myers Squibb Co.
Novartis
Amgen Inc.
Glaxosmithkline PLC
Kayropharma Therapeutics
Gilead Sciences
Adapta Immue
Genulex Corporation
SynerGene Therapeutics
shanghai sunway biotech
Key findings of the Study
By therapy, gene-induced immunotherapy was the highest contributor to the Cancer Gene Therapy Market size in 2020.
By end-user, the hospital segment dominated the market in 2020 and is expected to continue this trend during the forecast period.
Region-wise, North America garnered the largest revenue share in 2020; however, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: CANCER GENE THERAPY MARKET, BY THERAPY
CHAPTER 5: CANCER GENE THERAPY MARKET, BY END USER
CHAPTER 6: CANCER GENE THERAPY MARKET, BY REGION
CHAPTER 7: COMPANY LANDSCAPE
CHAPTER 8: COMPANY PROFILES
For more information about this report visit https://www.researchandmarkets.com/r/3cfb1a
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
